PUBLISHER: KBV Research | PRODUCT CODE: 1353487
PUBLISHER: KBV Research | PRODUCT CODE: 1353487
The Asia Pacific Sacral Nerve Stimulation Market would witness market growth of 5.8% CAGR during the forecast period (2023-2030).
A notable proportion of the population is affected by common problems with the bladder and intestines, including overactive bladder (OAB), urine retention, and faecal incontinence. There is an increasing need for efficient treatment options, such as sacral nerve stimulation, as these disorders are becoming more common. This procedure offers an opportunity for those unable to endure or have not reacted to conventional therapy.
Although it is still unknown how sacral nerve stimulation (SNS) improves fecal incontinence, it has become a helpful treatment choice in some individuals. The advantage may be related to central actions at the spinal cord or brain level or to direct peripheral effects on colorectal sensory or motor function.
SNM entails the percutaneous insertion of an electrode in the third sacral foramen and the subcutaneous implantation of a stimulating device in the buttocks. Although it is suggested that SNM stimulates anorectal function at a greater central level, the specific functioning mechanism of SNM is still completely unclear. SNM is recognized as a successful therapeutic option for fecal incontinence in the adult population. Less is known about SNM's pathophysiological impact on constipation. More information is now readily available about the usage of SNM in children in recent years.
India is one of the most populated nations in the world, and a significant portion of its population is 60 years of age or older. Furthermore, it is anticipated that India's elderly population will continue to grow. According to government estimates, the ratio will increase up to 11.1% in 2025 from 7.5% in 2010. According to the OECD, Japan has the greatest ratio of people 65 and older to people in the 20 to 64 age range per 100 people in the country as of 2017. By 2050, this ratio is expected to increase to 79 per 100. The incidence of diseases such as urological disorders is in danger due to the region's aging population, which could increase the need for sacral nerve stimulation. As a result, the regional market is anticipated to grow in the following years.
The China market dominated the Asia Pacific Sacral Nerve Stimulation Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $45.3 Million by 2030. The Japan market is anticipated to grow at a CAGR of 5.1% during (2023 - 2030). Additionally, The India market would register a CAGR of 6.4% during (2023 - 2030).
Based on Application, the market is segmented into Urinary & Fecal Incontinence, Chronic Anal Fissure, and Others. Based on Product, the market is segmented into Devices, and Accessories. Based on End User, the market is segmented into Hospitals, Specialty Clinics, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, Axonics, Inc., Beijing PINS Medical Co., Ltd., PZMed, Laborie Medical Technologies, Synapse BioMedical, Inc., Johnson and Johnson, LivaNova PLC, Boston Scientific Corporation, and Saluda Medical Pty Ltd.
Market Segments covered in the Report:
By Application
By Product
By End User
By Country
Companies Profiled
Unique Offerings from KBV Research
List of Figures